Viiv Healthcare

This study tested two experimental oral medications (VH4004280 and VH4011499) in 44 adults with HIV who had never taken HIV drugs before. The goal was to see how well these capsid inhibitors lower the amount of virus in the blood over 10 days. Researchers also checked for side ef…

This study tested a two-drug HIV pill (dolutegravir/lamivudine) in 32 teens aged 12-18 who had never taken HIV medication before. The goal was to see if this simpler daily pill could control the virus as well as standard three-drug regimens, while lowering the risk of long-term s…

This study looked at whether adults aged 50 and older living with HIV could safely switch from a three-drug pill to a simpler two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch and were f…

This study offers children and teens with HIV continued access to dolutegravir, a powerful HIV medication, after they finished earlier studies. About 100 participants who tolerated the drug well will receive age-appropriate doses every 12 weeks until the drug is locally approved …

This early-stage study tested a new experimental HIV drug called VH4524184 in 84 healthy adults to see if it is safe and how the body processes it. The study also checked whether the drug affects a key liver enzyme that can change how other medicines work. Because HIV requires li…

This study looked at two different methods for giving cabotegravir PrEP (an HIV prevention shot) to HIV-negative men who have sex with men and transgender men aged 18 and older. About 287 participants received the medication either after a one-month oral lead-in or directly as in…

This study looked at how to best give HIV prevention shots (called CAB PrEP) to Black cis and transgender women in the US. Researchers tested different ways to offer the shots in clinics and asked both patients and staff what worked well and what didn't. The goal was to make it e…

This study looked at how a new HIV drug, VH4524184, is absorbed by the body and how it interacts with other common medicines. It involved 126 healthy adults aged 18 to 60. The goal was to gather information, not to treat HIV, so participants did not have HIV. Results will help gu…

This study tested two different long-acting versions of the HIV drug cabotegravir in 56 healthy adults. The goal was to see how safe they are and how the body processes them, not to treat HIV. Participants received a single injection, and researchers measured drug levels and side…